Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Lantern Pharma Inc (LTRN)

Lantern Pharma Inc (LTRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 28,025
  • Shares Outstanding, K 11,255
  • Annual Sales, $ 0 K
  • Annual Income, $ -17,120 K
  • EBIT $ -18 M
  • EBITDA $ -18 M
  • 60-Month Beta 1.75
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.35

Options Overview Details

View History
  • Implied Volatility 440.03% (-313.05%)
  • Historical Volatility 204.47%
  • IV Percentile 76%
  • IV Rank 46.43%
  • IV High 857.88% on 02/18/26
  • IV Low 77.80% on 01/30/26
  • Expected Move (DTE 25) 0.85 (30.80%)
  • Put/Call Vol Ratio 0.42
  • Today's Volume 34
  • Volume Avg (30-Day) 100
  • Put/Call OI Ratio 0.26
  • Today's Open Interest 169
  • Open Int (30-Day) 572
  • Expected Range 1.91 to 3.61

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-0.54
  • Growth Rate Est. (year over year) +185,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.11 +146.40%
on 03/27/26
2.82 -3.01%
on 04/16/26
+0.60 (+28.40%)
since 03/20/26
3-Month
1.11 +146.40%
on 03/27/26
3.59 -23.82%
on 01/21/26
-0.86 (-23.82%)
since 01/20/26
52-Week
1.11 +146.40%
on 03/27/26
5.74 -52.39%
on 08/06/25
-0.69 (-20.03%)
since 04/17/25

Most Recent Stories

More News
Emerging Data for Lantern Pharma’s Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failure — With No Added Toxicity

Lantern Pharma Schedules Type C Meeting with the FDA to Advance HARMONIC™ Protocol Amendments Targeting This High-Need Population, Reflecting LP-300’s Novel Mechanism of Action and the Rapidly Evolving...

LTRN : 2.72 (+9.24%)
RedChip's Biotech Investor Conference Replays Now Available

ORLANDO, FL / ACCESS Newswire / April 20, 2026 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced that on-demand replays...

NXL : 0.4500 (-2.87%)
BIVI : 1.5300 (-1.92%)
SXTP : 1.7900 (+0.56%)
BFRG : 0.9992 (+0.49%)
LTRN : 2.72 (+9.24%)
Lantern Pharma Launches withZeta.ai — the World’s First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development — Subscriptions Now Open; Debut Events at Nasdaq MarketSite on 4/16 and at AACR 2026 from 4/17 to 4/22

Platform Now Available with Introductory, Academic, & Commercial Subscription Tiers Live Debut at Nasdaq MarketSite, New York City — April 16, 2026,...

LTRN : 2.72 (+9.24%)
Lantern Pharma Invites Investors, Analysts & Shareholders to Experience the Future of Drug Discovery via a Live Demo of withZeta.ai — the World's First Multi-Agentic Co-Scientist for Rare Cancers — 8:30 AM Eastern, April 9, 2026

Briefing to Feature a Live Walkthrough, Demonstration of Key Features, The Market Opportunity & Industry Need, Competitive Positioning, and Platform Monetization Strategy

LTRN : 2.72 (+9.24%)
RedChip Showcases Public Companies Driving Biotech Innovation at April 16 Virtual Investor Conference

ORLANDO, FL / ACCESS Newswire / April 2, 2026 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced its upcoming virtual...

NXL : 0.4500 (-2.87%)
BIVI : 1.5300 (-1.92%)
SXTP : 1.7900 (+0.56%)
BFRG : 0.9992 (+0.49%)
LTRN : 2.72 (+9.24%)
Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Year of Clinical Validation and Strategic Expansion Across Pipeline, AI Platform Advances Towards Commercialization, and Global Trial Milestones ...

LTRN : 2.72 (+9.24%)
New to The Street Broadcasts Show #740 on Bloomberg Television at 6:30 PM EST Featuring Medicus (MDCX), Acme Markets- Canton Foundation, Alpha Ton Capital (ATON), and Virtuix Holdings (NASDAQ:VTIX)

The show also broadcasts across MENA and Latin America as sponsored programming.

TRN : 32.03 (-2.79%)
PETV : 0.7990 (unch)
SNYR : 0.5004 (-4.61%)
ACXP : 2.28 (-4.20%)
IGC : 0.3149 (-6.25%)
VTIX : 6.60 (+6.97%)
LTRN : 2.72 (+9.24%)
NRXP : 3.11 (+21.96%)
YYGH : 1.5850 (-1.55%)
DVLT : 0.7358 (-2.93%)
VVOS : 1.0100 (+3.69%)
Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report

Lantern Pharma Inc. (NASDAQ: LTRN) (“Lantern” or the “Company”), an AI‑driven, clinical‑stage oncology company leveraging its proprietary RADR ® platform to transform the cost...

LTRN : 2.72 (+9.24%)
Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001

The Planned Multicenter Phase 1 Trial Will Evaluate STAR-001 as Monotherapy and in Combination with Spironolactone in Children with Relapsed or Refractory CNS Malignancies, Including ATRT, DIPG, GBM, Medulloblastoma,...

LTRN : 2.72 (+9.24%)
RedChip AI Investor Conference Replays Now Available Highlighting Companies Driving Innovation Across the AI Ecosystem

ORLANDO, FL / ACCESS Newswire / March 27, 2026 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced that on-demand replays...

CMHSF : 0.6278 (+3.70%)
ZEO : 0.8518 (+27.27%)
LTRN : 2.72 (+9.24%)
CSAI : 0.6225 (+1.04%)
SHAZ : 35.83 (-3.21%)

Business Summary

Lantern Pharma Inc.is a biotechnology company. It develops medicines for multi-drug treatment resistance cancers focusing on prostate and ovarian cancers. The company's drug candidate consist LP-100, LP-300 and LP-184 which are in clinical stage. Lantern Pharma Inc.is based in Dallas, Texas.

See More

Key Turning Points

3rd Resistance Point 3.13
2nd Resistance Point 2.93
1st Resistance Point 2.71
Last Price 2.72
1st Support Level 2.29
2nd Support Level 2.10
3rd Support Level 1.88

See More

52-Week High 5.74
Fibonacci 61.8% 3.97
Fibonacci 50% 3.43
Fibonacci 38.2% 2.88
Last Price 2.72
52-Week Low 1.11

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.